MRPS35 is a mitochondrial ribosomal protein that functions as a structural component of the mitochondrial small ribosomal subunit, participating in mitochondrial translation 1. It is located on chromosome 12 and contains RNA-binding and protein-binding domains essential for ribosomal assembly and function. MRPS35 plays a role in mitochondrial energy metabolism by participating in mitochondrial translational elongation and termination processes 1. In Langerhans cells, MRPS35 is preferentially expressed following TNF-α stimulation and is associated with mitochondrial activation and cellular metabolism, highlighting its involvement in metabolic adaptation during immune cell activation 2. Clinically, MRPS35 has relevance in multiple disease contexts. High expression of MRPS35 significantly indicates poor prognosis in breast cancer patients, and the gene was identified as part of an MRP family prognostic nomogram for individualized risk prediction 1. Additionally, MRPS35 has been identified as a candidate disease gene in genetic disease screening, appearing among genes with potential pathogenic variants in diverse Mendelian phenotypes 3. An MRPS35-derived neoantigen has been shown to be immunogenic in pancreatic cancer models, suggesting potential therapeutic applications in cancer immunotherapy 4. These findings position MRPS35 as both a fundamental component of mitochondrial protein synthesis and an emerging biomarker with potential clinical significance in cancer prognosis and treatment.